A Study to Investigate if Long Acting Cabotegravir (CAB) and Lenacapavir (LEN) Injections Are Tolerable and Acceptable When Administered to Healthy Adults Without HIV (NCT06970223)

🧪 Interventions in This Study

• Cabotegravir long-acting (DRUG)
• Lenacapavir long-acting (DRUG)

Full eligibility criteria are available on the official NIH protocol. View the criteria ↗

📍 All Participating Trial Locations (1 Sites)

• GSK Investigational Site — Long Beach, California

💰 Cost, Insurance & Patient Rights

• 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
• Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
• Voluntary Participation: You may withdraw at any time without affecting your standard medical care.

More studies in HIV Infections

• Testing a Real-time Electronic Antiretroviral Adherence Monitoring Intervention — Chicago, Illinois
• The Ganchero Intervention for Migrant People Who Inject Drugs From Puerto Rico in New York City — New York, New York
• Efficacy, Safety and Tolerability Study of Long-acting Cabotegravir Plus Long-acting Rilpivirine (CAB LA + RPV LA) in Human-immunodeficiency Virus-1 (HIV-1) Infected Adults — Birmingham, Alabama
• Clinical Decision Support for PrEP — Los Angeles, California
• Peer Supported Collaborative Care Mental Health and Substance Use Disorder Care — Baltimore, Maryland
• A Study to Assess the Safety and Pharmacokinetics of a Human Monoclonal Antibody (VH4527079) in Healthy Adults and Persons With HIV — Las Vegas, Nevada

Explore by condition: All HIV Infections clinical trials

💡 How to Participate

1. Check the checklist above to see if you may qualify.
2. Review the official NIH record below to find the coordinating site.
3. Ask about the visit schedule, what is covered at no cost, and any travel support.
4. Confirm with your own doctor before making a decision.